"A world-wide prospective study of INC on prognosis and biomarkers in GBS"

A world-wide prospective study of INC on prognosis and biomarkers in GBS

International Guillain-Barré syndrome outcome study (IGOS)_new

2012
In 2012 an international team of expert neurologists and scientists decided to join forces and start the International GBS Outcome Study (IGOS), aiming to collect the world’s largest high-quality data/biobank for further research.




2016
By 2016 – 100 years since the description of Guillain Barré Syndrome – the international team had expanded considerably. Nowadays the IGOS Consortium consists of researchers and clinicians from 143 centres in 21 countries across 5 continents.



2024
Together we included 2000 patients with the Guillain-Barré Syndrome (GBS) from 21 countries across 5 continents. All patients diagnosed with GBS are included, independent of age, severity, variant, treatment, and disease course.

IGOS is the largest real-world database on GBS worldwide containing clinical data, biomaterial, electrophysiology and questionnaires on patient-reported outcome measures. Data are collected at standardized timepoints for up to three years after hospital admission. Follow-up was finalized in May 2024.The online database for IGOS which was designed for the inclusion of patients and the collection of clinical data will be closed in December 2024.

New IGOS website

A new website for IGOS has been developed to share information on projects and for applications. The new website consists of  two parts; a public part and a part especially for members. This part is accessible by a secured login. There will be no patient data on this new website. One can send a request for data, which will be shared via the DRE.


For more information please visit: www.igosresearch.com